| Project/Area Number |
25462200
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
近藤 展行 兵庫医科大学, 医学部, 講師 (50402889)
松本 成司 兵庫医科大学, 医学部, 講師 (60412011)
多久和 輝尚 兵庫医科大学, 医学部, 講師 (00412049)
橋本 昌樹 兵庫医科大学, 医学部, 助教 (40461074)
黒田 鮎美 兵庫医科大学, 医学部, 助教 (90642570)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 中皮腫 / 悪性胸膜中皮腫 |
|---|
| Outline of Final Research Achievements |
We could confirm the antitumor effect of mTOR inhibitor against malignant pleural mesothelioma cell lines in vivo and mouse subcutaneous model. We focused on a PI3K/mTOR inhibitor that inhibits both mTOR and PI3K, which is upstream of mTOR, as a measure for possible resistance development. In H2052, which is most sensitive to PI3K/mTOR inhibitors, expression of gene (F) was decreased compared with other cell lines. When gene (F) was inactivated in the wild-type cell line, enhancement of mTOR phosphorylation was confirmed. In immunostaining of surgical specimens, multivariate analysis suggested that p-mTOR could be a therapeutic target. In gene (F)-deficient mesothelioma cell line, subcutaneous tumor growth was significantly reduced by treatment with a PI3K/mTOR inhibitor compared to untreated group.
|
